Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.43 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.43 |
| ▸ | ITGB7 | P26010 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 6/20 | 0.43 |
| ▸ | TP53 | P04637 | 4/20 | 0.43 |
| ▸ | UTRN | P46939 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6612158 | 0.89 | MAOA (0.62) | MAOAADRA1ASMN1; SMN2KDM4ENPC1 | |
| SCHEMBL6617271 | 0.79 | SMN1; SMN2 (0.41) | MAOAADRA1ASMN1; SMN2KDM4ENPC1 | |
| SCHEMBL2242151 | 0.78 | SMN1; SMN2 (0.71) | SMN1; SMN2KDM4ENPC1ALDH1A1RAB9A | |
| SCHEMBL6614014 | 0.78 | KDM4E (0.58) | SMN1; SMN2KDM4ENPC1ALDH1A1ITGB1 | |
| SCHEMBL6614642 | 0.77 | SMN1; SMN2 (0.40) | MAOAADRA1ASMN1; SMN2KDM4ENPC1 | |
| SCHEMBL19029185 | 0.75 | HDAC6 (0.68) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL27606520 | 0.74 | UTRN (0.45) | SMN1; SMN2KDM4ENPC1ALDH1A1RAB9A | |
| SCHEMBL6617716 | 0.73 | MAOA (0.36) | MAOAADRA1ASMN1; SMN2KDM4ENPC1 | |
| SCHEMBL6614228 | 0.73 | HPSE (0.55) | KDM4EITGB1ITGA4ITGB7 | |
| SCHEMBL31430575 | 0.73 | MAOA (0.45) | MAOAADRA1ASMN1; SMN2KDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040209776-A1 | Azole derivatives useful as insecticide | FAROOQ SALEEM | 2004-10-21 | — | — | US | disclosed |
| CN-1533389-A | Azole derivatives useful as insecticide | — | 2004-09-29 | — | — | CN | disclosed |
| EP-1414818-A1 | AZOLE DERIVATIVES USEFUL AS INSECTICIDE | Syngenta Limited (GB) | 2004-05-06 | — | — | EP | disclosed |
| EP-1412325-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS, PROCESS FOR THEIR USE AS MEDICAMENT FOR THE TREATMENT OF CNS DISORDERS, OBESITY AND TYPE II DIABETES | BIOVITRUM AB (SE) | 2004-04-28 | — | — | EP | disclosed |
| WO-2003011861-A1 | AZOLE DERIVATIVES USEFUL AS INSECTICIDE | SYNGENTA LIMITED (GB) | 2003-02-13 | — | — | WO | disclosed |
| WO-2002100822-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS, PROCESS FOR THEIR USE AS MEDICAMENT FOR THE TREATMENT OF CNS DISORDERS, OBESITY AND TYPE II DIABETES | BIOVITRUM AB (SE) | 2002-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209776-A1 | Azole derivatives useful as insecticide | CYP8B1, HRH2, API5 | MAOA 2012/4885ADRA1A 1063/4885SMN1; SMN2 3030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.